Long Term Study With B2036-PEG

Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG -

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00143416

Enrollment

Registered

2005-09-02

Start date

2004-04-30

Completion date

2007-07-31

Last updated

2008-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly

Brief summary

Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.

Interventions

DRUGPegvisomant

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009).

Exclusion criteria

* Switching to other therapeutic methods for acromegaly

Design outcomes

Primary

Measure	Time frame
To evaluate the safety and efficacy of long-term B2036-PEG therapy in patients with acromegaly	—

Secondary

Measure	Time frame
PK/PD evaluation	—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026